An innovative antibody durably reduces cholesterol with spaced-out injections

LDL cholesterol, often referred to as “bad cholesterol,” plays a key role in the development of cardiovascular diseases, the leading cause of mortality worldwide. Despite the effectiveness of statins, many patients fail to reach recommended targets or discontinue treatment due to the frequency of doses or side effects. A new therapeutic approach could change the game.

Recaticimab is a monoclonal antibody designed to block PCSK9, a protein that reduces the liver’s ability to remove LDL cholesterol from the bloodstream. Unlike other similar treatments, it incorporates a genetic modification called the YTE mutation, which extends its duration of action in the body. Thanks to this innovation, recaticimab can be administered every 4, 8, or even 12 weeks, compared to every 2 or 4 weeks for other anti-PCSK9 antibodies. This significantly reduces the number of annual injections, from 24 to 52 down to just 12 per year.

Phase III clinical trials have demonstrated that recaticimab achieves powerful and sustained reductions in LDL cholesterol, whether as monotherapy or in combination with statins. The results show an average LDL reduction of up to 60%, with a favorable safety profile. Patients with cardiovascular diseases or type 2 diabetes, who require strict cholesterol control, also benefit from this efficacy, even with extended dosing intervals.

The YTE mutation enhances recaticimab’s binding to a specific receptor, the neonatal Fc receptor, which protects the antibody from degradation. This allows effective concentrations to be maintained in the blood for long periods without requiring dose adjustments. Additionally, the treatment acts quickly: LDL cholesterol levels begin to drop within the first days following injection.

Another major advantage is the flexibility of the dosing regimen. Doctors can adjust the frequency of injections based on patient needs and preferences, which could improve treatment adherence. Indeed, one of the main challenges of current cholesterol therapies is poor patient adherence, often due to the complexity of regimens or the frequency of injections. With recaticimab, the reduced number of administrations could mitigate these barriers.

Studies have also shown that recaticimab is well-tolerated. The most common adverse effects, such as injection site reactions, remain mild and temporary. Furthermore, the development of antibodies against the drug—a phenomenon that can reduce the effectiveness of some treatments—appears limited and without significant impact on results or safety.

Although current data primarily come from studies conducted in China, the results are promising. Recaticimab could offer a solution for patients who struggle to follow regular treatment while maintaining effective cholesterol reduction. Its annual cost is also comparable to that of other anti-PCSK9 antibodies, which could facilitate access.

By targeting a precise biological mechanism and optimizing duration of action, this treatment represents a major advance in simplifying cholesterol management. It could thus help reduce the burden of cardiovascular diseases, provided its efficacy is confirmed in larger and more diverse populations.

Site Sources

Official Study Source

DOI: https://doi.org/10.1007/s40265-026-02348-4

Title: Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering

Journal: Drugs

Publisher: Springer Science and Business Media LLC

Authors: Sha Li; Ying Gao; Cheng-Gang Zhu; Jian-Jun Li